Schwab Charles Investment Management Inc. Grows Stake in Cryolife Inc (CRY)

Schwab Charles Investment Management Inc. boosted its holdings in shares of Cryolife Inc (NYSE:CRY) by 14.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 171,089 shares of the medical equipment provider’s stock after purchasing an additional 21,298 shares during the quarter. Schwab Charles Investment Management Inc. owned about 0.51% of Cryolife worth $3,884,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Wells Fargo & Company MN increased its position in shares of Cryolife by 0.9% during the 2nd quarter. Wells Fargo & Company MN now owns 31,313 shares of the medical equipment provider’s stock valued at $624,000 after purchasing an additional 271 shares during the last quarter. Rhumbline Advisers increased its position in shares of Cryolife by 0.7% during the 2nd quarter. Rhumbline Advisers now owns 57,291 shares of the medical equipment provider’s stock valued at $1,143,000 after purchasing an additional 387 shares during the last quarter. Nationwide Fund Advisors increased its position in shares of Cryolife by 3.2% during the 2nd quarter. Nationwide Fund Advisors now owns 24,351 shares of the medical equipment provider’s stock valued at $486,000 after purchasing an additional 744 shares during the last quarter. Oppenheimer & Co. Inc. increased its position in shares of Cryolife by 4.6% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 18,655 shares of the medical equipment provider’s stock valued at $372,000 after purchasing an additional 818 shares during the last quarter. Finally, Connors Investor Services Inc. boosted its holdings in Cryolife by 0.9% during the 2nd quarter. Connors Investor Services Inc. now owns 108,907 shares of the medical equipment provider’s stock valued at $2,173,000 after acquiring an additional 932 shares during the period. 73.64% of the stock is currently owned by institutional investors.

A number of equities analysts recently issued reports on the company. Zacks Investment Research cut Cryolife from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. Lake Street Capital boosted their price objective on Cryolife to $26.00 and gave the company a “buy” rating in a report on Wednesday, October 11th. Canaccord Genuity reiterated a “buy” rating and issued a $25.00 target price on shares of Cryolife in a report on Wednesday, January 3rd. Northland Securities reiterated a “buy” rating and issued a $23.50 target price on shares of Cryolife in a report on Monday, November 13th. Finally, TheStreet cut Cryolife from a “b” rating to a “c+” rating in a report on Monday, October 30th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $23.63.

Shares of Cryolife Inc (NYSE CRY) traded down $0.40 during midday trading on Friday, hitting $18.25. The company had a trading volume of 71,574 shares, compared to its average volume of 84,557. Cryolife Inc has a 1 year low of $14.02 and a 1 year high of $24.00. The stock has a market cap of $610.61, a PE ratio of 44.51 and a beta of 0.77. The company has a quick ratio of 4.90, a current ratio of 5.96 and a debt-to-equity ratio of 0.29.

In other news, CAO Amy Horton sold 4,000 shares of the stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $19.00, for a total value of $76,000.00. Following the transaction, the chief accounting officer now directly owns 98,705 shares of the company’s stock, valued at $1,875,395. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO David Ashley Lee sold 33,190 shares of the company’s stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $19.00, for a total value of $630,610.00. Following the completion of the sale, the chief financial officer now owns 324,339 shares in the company, valued at approximately $6,162,441. The disclosure for this sale can be found here. Insiders have sold a total of 59,190 shares of company stock worth $1,138,240 over the last ninety days. 6.00% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: “Schwab Charles Investment Management Inc. Grows Stake in Cryolife Inc (CRY)” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/04/schwab-charles-investment-management-inc-has-3-88-million-holdings-in-cryolife-inc-cry.html.

Cryolife Company Profile

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Institutional Ownership by Quarter for Cryolife (NYSE:CRY)

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply